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Background/aim: The myasthenia gravis-quality of life questionnaire 15 item (MG-QOL15) is a validated, short, and easy to use
disease-specific quality of life (QOL) tool in myasthenia gravis. Other than Turkish, a lot of versions of the MG-QOL15 have been
used in different languages in different cultures. Therefore, the aim of this study was to translate and construct a validated and adapted
Turkish version of the MG-QOL15 [MG-QOL15(T)].
Materials and methods: After translation, back-translation, and comparison of the 2 English versions of the MG-QOL15, it was tested
by 22 monolingual healthy individuals and then 23 patients with clinically stable MG. Afterwards, 11 voluntary patients out of these 23
patients were interviewed for a second time. During the second interview, the MG-QOL15(T) and the 36-item short-form health survey
(Turkish version) were administered simultaneously.
Results: The MG-QOL15(T) was found to have high internal consistency (1st and 2nd evaluation Cronbach’s alphas were 0.958
and 0.928, respectively), test–retest reliability, and concurrent validity. The MG-QOL15(T) was negatively correlated with physical
functioning, general health, vitality, and social functioning domains and with the physical and mental composite scores of the SF-36.
Conclusion: The MG-QOL15(T) is accepted to be a valid, reliable, valuable tool for measuring disease-specific QOL in Turkish patients
with MG.
Key words: Myasthenia gravis, quality of life, questionnaire

1. Introduction
Myasthenia gravis (MG) is a chronic autoimmune
disease that is generally treatable. It results in fatigue and
fluctuating muscle weakness. Although some patients
experience remission of variable duration, most experience
a stable disease course characterized by muscle weakness
that worsens with exertion and attenuates with rest. The
residual myasthenic symptoms may negatively affect
patients’ perceived health-related quality of life (QOL)
(1,2). The report of the QOL by the patients may influence
therapeutic decisions and enable a better understanding
of his/her demands, paving the way for optimal clinical
support (3).
When the quality of life questionnaire is specific it
could detect items relevant to the disease more easily. The
myasthenia gravis-quality of life questionnaire 15-item
scale (MG-QOL15) is one such questionnaire. It originated
* Correspondence: ntascilar@medipol.edu.tr

from a list of 60 items covering specific features of health
related-QOL in MG. It is a validated, short, useful, and
easy to use tool for evaluating health related QOL that can
inform the physician of the patient’s perception of MGrelated dysfunction (4,5).
To date, there has been no Turkish disease specific
quality of life instrument validated for use in evaluating
Turkish patients with MG. This study aimed to translate
and construct a validated and adapted Turkish version of
the MG-OQL15 [MG-QOL15(T)].
2. Materials and methods
2.1. Patients
The inclusion criteria for patients were as follows; (1) a
diagnosis of ocular or generalized MG, based on a clinical
examination and supported by the presence of acetylcholine
receptor antibodies (AchRAb), a positive neostigmine test,
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and/or neurophysiologic evidence of a neuromuscular
junction disorder (abnormal repetitive nerve stimulation or
abnormal single-ﬁber electromyography studies), and (2)
unchanged therapy during the 6 months preceding the study.
At the time of the study, there were 23 registered
physically and cognitively intact patients with clinically
stable MG in the outpatient clinic of the hospital of the
Medical Faculty of Bülent Ecevit University who fulfilled
the above-mentioned criteria. All of them were included
in the study and given the MG-QOL15(T). Afterwards,
for the evaluation of the test–retest reliability and validity,
all of them were phoned and asked to come for a second
evaluation, but only 11 of them volunteered to come on the
scheduled day (15 days after the first interview). Therefore,
the scores of 23 patients in the first interview were taken
into consideration for the evaluation of the first internal
consistency. As for the evaluation of test–retest reliability
and construct validity the scores of the second interview of
11 patients were analyzed.
The study was reviewed and approved by the Bülent
Ecevit University Clinical (No. 2012/03-15) and İstanbul
Medipol University (No. 2015/03-136) noninterventional
clinical research review boards. In addition, a written
informed consent was obtained from each patient.
Clinical severity and classification were determined by
the MG composite score (6,7) and the MG Foundation of
America (MGFA) clinical classification (8), respectively.
2.2. The adaptation procedure
The original MG-QOL15 has 15 items. Each item is scored
from 0 to 4 according to its frequency, scoring a maximum
of 60. The higher the score, the worse is the perceived
quality of life by the patient (4). In this study, at all stages
of the adaptation, conceptual translation was considered
more important than linguistic translation. Four associate
professors from different fields of medicine who were
fluent in English produced independent translations of
the original MG-QOL15. Then they met as a group to
agree on the translations that most adequately reflected
the concept expressed by the English items. Next, this
revised version was back-translated into English by a
freelance translator (notarized)/interpreter. Finally, a
bilingual English teacher (who was born and raised in
Australia and has Turkish parents) compared the original
English questionnaire with the revised-translated version,
and any discrepancies were corrected in the Turkish text
to maintain the original meaning. Then, for the second
step of adaptation, the Turkish items were tested by 22
monolingual healthy individuals (8 elementary education
level, 6 high school level, 5 college education level, 3
university level). This procedure ensured that the level of
language used in the questionnaire would be appropriate
for potential respondents. Every item other than item 10
was easily understood and answered correctly. Instead of
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scoring item 10, some participants wrote “I don’t know
driving” or left it unanswered: These answers were taken
as incorrect. Finally, after the agreement of all members
regarding the equivalence of the final Turkish version to
the original English version, this final Turkish version
[MG-QOL15(T)] was used in the testing phase (Figure).
For the third step in the adaptation, the MG-QOL15(T)
and MG composite were administered to 23 patients with
clinically stable MG.
2.3. Assessing reliability and construct validity
The above-mentioned 23 patients’ scores of MG-QOL15(T)
were used in the evaluation of internal consistency of MGQOL15(T). Item 10 of the MG-QOL15(T) was answered
incorrectly by 12 patients.
Then 11 out of above-mentioned 23 patients who
volunteered to participate in the second part of the study
were interviewed twice, with a 2-week interval between
the assessments, which is considered a necessary time
interval, as suggested by other studies in Turkey (9). This
period is long enough for patients not to remember their
answers to questions and short enough for no change in
the severity and classification of MG that could affect the
answers and impair test–retest reliability. The patients’
condition and treatment procedures did not change at
all in this period. During this second interview, the MGcomposite, MG-QOL15(T), and the Turkish version of
the Medical Outcomes Study 36-item short-form health
survey (SF-36), which was validated in a group of patients
with rheumatoid disorders in 1999 (10) and then in 419
Turkish cancer patients in 2005 (11), were administered.
Item 10 of the MG-QOL15(T) was answered incorrectly
by 6 patients. The SF-36 measures 8 domains that represent
8 general health dimensions: physical functioning, role
functioning-physical, bodily pain, general health, vitality,
social functioning, role functioning-emotional, and
mental health. The first 4 domains are physical and the
last 4 are mental. Two composite scores are available to
summarize these scales: the physical composite score and
the mental composite score.
The same interviewer conducted both the MG-QOL15
(T) and the SF-36 interviews and the MG composite with
all patients in all sessions.
In the validation studies, item-specific internal
consistency (in 23 and 11 patients, in the 1st and 2nd
evaluation, respectively), test–retest reliability (in 11
patients), and construct validity (in 11 patients) of the
MG-QOL15(T) were tested.
The “internal consistency” of an instrument is an
estimate of the degree to which its constituent items are
interrelated. Cronbach’s alpha coefficient is generally
employed and coefficients can range from 0 to 1. “Test–
retest reliability” is an estimate of the degree of random
measurement error produced by the instrument. It is
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Adı Soyadı:

Tarih:

Lütfen, aşağıdaki seçeneklerden sizin için doğru olanı işaretleyiniz (Son 1 Ay için)

1. Rahatsızlığım beni sinirlendiriyor.

0

1

2

3

4

Hiç

Az

Orta

Fazla

Çok
fazla

2. Gözlerimi kullanmakta zorlanıyorum.
3. Yemede-içmede zorlanıyorum.
4. Rahatsızlığımdan dolayı sosyal
aktivitelerimi sınırladım.
5. Rahatsızlığım hobilerimden ve eğlenceden
zevk almamı engelliyor.
6. Ailemin ihtiyaçlarını karşılamakta
zorlanıyorum.
7. Planlarımı rahatsızlığımı dikkate alarak
yapmalıyım.
8. Mesleki becerilerim ve işyerindeki durumum
kötü etkilendi.
9. Konuşmakta zorlanıyorum.
10. Araba kullanırken zorlanıyorum.
11. Rahatsızlığımdan dolayı moralim bozuk.
12. Yürümekte zorlanıyorum.
13. Sokakta, çarşıda, pazarda dolaşmakta
zorlanıyorum.
14. Rahatsızlığımdan dolayı kendimi kapana
kısılmış hissediyorum.
15. Kişisel bakımımı (banyo yapmakta, traş
olmakta, vs) sağlamakta zorlanıyorum.
Myasthenia Gravis Quality-of-Life
“MG-QOL15”
Burns TM ve ark. Muscle and Nerve 2008

Toplam MG-QOL15(T) skoru

Figure. The MG-QOL15(T) questionnaire.

assessed by comparing instrument scores at 2 time points,
given that there has been no change in condition between
administrations. “Construct validity” is generally assessed
by comparing scores on the instrument with those
obtained from a measure assessing a related construct (9).
This property was assessed by comparing MG-QOL15(T)
with the Turkish version of the SF-36.
2.4. Statistical analysis
Incorrect answers obtained from the MG-QOL(T)
questionnaire on item 10 were scored as 0 [although this
issue will be solved in the new version of MG-QOL15 until

then it is recommended to be scored as ‘0’ by the original
makers of the instrument (*see footnote)]. Descriptive
measurements of the numerical values included the mean
and standard deviation (SD). Categorical variables are
presented as count and percent frequency. The Shapiro–
Wilk test was used to assess the normality of the numerical
variables such as age and total scores. The internal
consistency of the quality of life scale was investigated with
Cronbach’s alpha (CA) in the first and second evaluation,
separately. In addition, test–retest reliability was
investigated by using intraclass correlation (ICC) between

* The investigators of the MG-QOL15 are in the process of modifying their scale so that the driving item is a broader item, focusing on
“independence” for activities beyond driving. They have studied rewording. The future, modified scale (not yet submitted for publication,
but studied) will address this concern. However, both scales (the existing and future) are validated, both in past studies and in future,
to-be-published scales. This does not invalidate our work. In the future, we will decide whether to study the future scale in more detail.
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the first and second measurement of each item and total
scores. Furthermore, simple Spearman’s rank correlation
coefficient was used for the validity of the quality of life
scale. The statistical significance was considered as a P
value of less than 0.05. All computations were made using
PASW Statistics 18.0 [SPSS (Hong Kong) Ltd, Rm 1804,
18/F, Westlands Centre, Westlands Road, Quarry Bay,
Hong Kong, China].
3. Results
To produce meaningful and easily understandable Turkish
expressions, it was necessary to change the structure and
words used in some of the English items. These changes
reflected the differences in grammar between the 2
languages. Furthermore, some items, such as “public
places”, are not common expressions for Turkish speakers.
Thus, “public places” was translated as “street, market,
bazaar” (Table 1).
In the first evaluation 12 out of 23 patients were female,
and the average age (± SD) was 55.8 (±12.8) years, ranging
from 18 to 85. MG composite scores obtained were between
0 and 24 (with a mean ± SD of 6.9 ± 6.9). MG composite
scores and MG-QOL15(T) total scores were not different

between sexes (P = 0.667 and P = 0.469, respectively). Four
out of 23 patients were class I and 19 patients were Class
II according to MGFA clinical classification. MG duration
(± SD) was 56.9 months, ranging from 6 to 264 months.
In the second evaluation, 8 out of the 11 patients
were female, and the average age (±SD) was 56 (±17.1)
years, ranging from 18 to 85 years. MG composite scores
obtained were between 0 and 21 (with a mean ± SD of 5.7
± 5.5). All of the patients were Class II according to the
MGFA clinical classification.
Distribution of the components of the MG-QOL15(T),
internal consistency of the 1st (in 23 patients) and 2nd (in
11 patients) tests, and test–retest reliability (in 11 patients)
are shown in Tables 2 and 3. In the first evaluation, the
highest mean score was observed in item 7 (mean = 1.74 ±
1.32) and, in the second evaluation, the highest mean score
was observed in item 11 (mean = 1.73 ± 1.27). The internal
consistency was high in the Turkish version (CAfirst (n = 23) =
0.958 and CAsecond (n = 11) = 0.928). Although a decrease in the
number of patients caused a decrease in CA in the second
evaluation, it was still found to be statistically significant
(P < 0.001). In Table 3, changes in CA values whenever one
of the items was removed are shown. In both evaluations,

Table 1. Changes made because of the differences in grammar of the 2 languages.
Original items

Changes made while translating into English

Please indicate how true each statement has been (over the past 4 weeks)

Please, from the choices below, mark the accurate one for you (for the last month)

0: Not at all, 1: A little bit, 2: Somewhat, 3: Quite a bit, 4: Very much

0: Never, 1: Rarely, 2: Sometimes, 3: Often, 4: Usually

1.

I am frustrated by my condition

My condition is making me angry

2.

I have trouble using my eyes

I have difficulty using my eyes

3.

I have trouble eating

I have difficulty eating/drinking

4.

I have limited my social activity because of my condition

I have limited my social activities because of my condition

5.

My condition limits my ability to enjoy hobbies and fun activities

My condition prevents me from enjoying my hobbies and having fun

6.

I have trouble meeting the needs of my family

I am having difficulty meeting the needs of my family

7.

I have to make plans around my condition

I should make my plans taking my condition into consideration

8.

My occupational skills and job status have been negatively affected

My professional skills and my work situation have been badly affected

9.

I have difficulty speaking

I am having difficulty speaking

10.

I have trouble driving

I have difficulty driving

11.

I am depressed about my condition

I am depressed because of my condition

12.

I have trouble walking

I am having difficulty walking

13.

I have trouble getting around public places because of MG

I am having difficulty walking around in the street, market, bazaar

14.

I feel overwhelmed by my condition

I feel trapped because of my condition

15.

I have trouble performing my personal grooming needs

I am having difficulty tending to my personal needs (taking a bath, shaving, etc.)

Total MG-QOL15 score

Total MG-QOL15 score
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Table 2. Descriptive values of the components of the MG-QOL15(T) in the first and second evaluation of MG patients.

Original items

First evaluation
(n = 23 patients)

Second evaluation
(after 2 weeks, n = 11 patients)

0%

1%

2%

3%

4%

Mean ± standard
deviation

0%

1%

2%

3%

4%

Mean ± standard
deviation

1. I am frustrated by my condition

21.7

21.7

26.1

26.1

4.3

1.70 ± 1.22

18.2

18.2

54.5

0

9.1

1.64 ± 1.12

2. I have trouble using my eyes

34.8

13.0

21.7

17.4

13.0

1.61 ± 1.47

27.3

18.2

36.4

0

18.2

1.64 ± 1.43

3. I have trouble eating

60.9

17.4

8.7

13.0

0

0.74 ± 1.10

54.5

18.2

2.7.3

0

0

0.73 ± 0.91

4. I have limited my social activity because of my
condition

52.2

0

21.7

17.4

8.7

1.3 ± 1.49

54.5

18.2

18.2

9.1

0

0.82 ± 1.08

5. My condition limits my ability to enjoy hobbies
52.2
and fun activities

13.0

8.7

13.0

13.0

1.22 ± 1.54

40

20

20

0

20

1.40 ± 1.57

6. I have trouble meeting the needs of my family

47.8

13.0

17.4

13.0

8.7

1.22 ± 1.41

36.4

27.3

18.2

0

18.2

1.36 ± 1.50

7. I have to make plans around my condition

26.1

13.0

30.4

21.7

8.7

1.74 ± 1.32

10

60

10

10

10

1.50 ± 1.17

8. My occupational skills and job status have been
42.9
negatively affected

14.3

19.0

9.5

14.3

1.38 ± 1.50

55.6

22.2

22.2

0

0

0.67 ± 0.86

9. I have difficulty speaking

52.2

30.4

8.7

4.3

4.3

0.78 ± 1.08

63.6

18.2

0

18.2

0

0.73 ± 1.19

10. I have trouble driving

73.9

13.0

13.0

0

0

0.39 ± 0.72

81.8

9.1

9.1

0

0

0.27 ± 0.65

11. I am depressed about my condition

34.8

17.4

8.7

26.1

13.0

1.65 ± 1.53

9.1

45.5

27.3

0

18.2

1.73 ± 1.27

12. I have trouble walking

34.8

13.0

13.0

30.4

8.7

1.65 ± 1.46

45.1

9.1

27.3

9.1

9.1

1.27 ± 1.42

13. I have trouble getting around public places
because of MG

27.3

22.7

13.6

27.3

9.1

1.68 ± 1.39

54.5

18.2

18.2

9.1

0

0.82 ± 1.08

14. I feel overwhelmed by my condition

56.5

4.3

13.0

17.4

8.7

1.17 ± 1.50

45.5

27.3

9.1

0

18.2

1.18 ± 1.54

15. I have trouble performing my personal
grooming needs

47.8

26.1

13.0

8.7

4.3

0.96 ± 1.18

72.7

18.2

0

0

9.1

0.55 ± 1.21

Total score

it is observed that in the measurement of CA values during
the one-by-one removal of items, there was no significant
difference in internal consistency, and all the values were
above 0.90.
In the test–retest reliability analysis, which tested
repeatability of the MG-QOL15(T), ICC scores ranged
between 0.391 and 0.970: The scores for items 1, 2, 4, 6, 10,
11, 12, 13, 14, and 15, and the total MG-QOL15(T) score
were significantly higher (P < 0.05). ICC of the total MGQOL15(T) was 0.882 (P = 0.001). The lowest ICC values
were observed only for questions 3, 5, 7, 8, and 9 (Table 3).
The MG-QOL15(T) total scores were compared with
the domain and summary scores of the SF-36. The MGQOL15(T) was negatively correlated with the physical
functioning (P = 0.001; r = −0.841), general health (P =
0.005; r = −0.778), vitality (P = 0.005; r = −0.771), and
social functioning (P = 0.001; r = −0.833) domains and
with the physical and mental composite scores (P = 0.005;
r = −0.779 and P = 0.007; r = −0.753, respectively) of the
SF-36 (supplemental data). Age and sex did not affect
the MG composite, SF-36, or MG-QOL15(T) scores.
Furthermore, MG composite scores were positively

19.0 ± 15.67

15.91 ± 12.28

correlated with the MG-QOL15(T) scores (P = 0.006; r =
0.555) (Supplemental data).
4. Discussion
The MG-QOL15(T) was well understood and accepted
by the patients. The MG-QOL15(T) was found to be a
reliable and valid questionnaire for Turkish patients with
MG. It generally had high internal consistency in both
evaluations and test–retest reliability. The scores of 10
questions and the total score of the MG-QOL15(T) were
found to have a high ICC upon repeating the test 2 weeks
apart, suggesting that the MG-QOL15(T) had a test–retest
reliability. Although MG-QOL15(T) was found to be a
reliable test, we did not know the reasons for the low scores
in 5 items. We could only speculate that it could be due to
the long period [2 weeks instead of 2 days as was applied
in some of the earlier Japanese studies (12)]. Patients
might not remember, or the low correlation between the
2 tests could be due to the nature of MG itself, because
the persistent experience of weakness could be perceived
differently during time, or the variation may be due to
the time in the day (morning/ afternoon) that the tests
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Table 3. Distribution of the internal consistency of the 1st and 2nd tests, and test–retest reliability in MG patients.

Original items

*Cronbach’s alpha
if item deleted in first
evaluation (n = 23)

*Cronbach’s alpha
if item deleted in second
evaluation (n = 11)

ICC between
first and second
evaluation

P value
for ICC

1. I am frustrated by my condition

0.955

0.930

0.790

0.008

2. I have trouble using my eyes

0.954

0.925

0.799

0.007

3. I have trouble eating

0.959

0.925

0.577

0.087

4. I have limited my social activity because of my condition

0.952

0.923

0.733

0.020

5. My condition limits my ability to enjoy hobbies and fun activities

0.953

0.915

0.516

0.125

6. I have trouble meeting the needs of my family

0.952

0.923

0.774

0.011

7. I have to make plans around my condition

0.957

0.926

0.479

0.150

8. My occupational skills and job status have been negatively affected

0.953

0.920

0.518

0.123

9. I have difficulty speaking

0.957

0.919

0.391

0.214

10. I have trouble driving

0.962

0.934

0.725

0.022

11. I am depressed about my condition

0.953

0.920

0.712

0.026

12. I have trouble walking

0.958

0.919

0.970

< 0.0001

13. I have trouble getting around public places because of MG

0.954

0.921

0.899

< 0.0001

14. I feel overwhelmed by my condition

0.952

0.918

0.856

0.002

15. I have trouble performing my personal grooming needs

0.954

0.917

0.898

< 0.0001

Total score

0.958

0.928

0.882

0.001

ICC: Intraclass correlation. * values for the remaining questions with the relevant question omitted. Note: P values presented were for testing the null hypothesis that there is
“no correlation”, which means that if the P value of the given question was less than 0.05, pre- and posttest results of that question was not significantly different.

applied. Furthermore, in our patients, although they are
given the instruction as “during the last month” they could
have marked some items according to the last few hours,
days, or the last week. Even if the MG-QOL15(T) is found
to be a reliable valid questionnaire, in order to identify
the exact reason for this problem multiple large groups of
MG patients should be enrolled in another study, in which
the MG-QOL15(T) questionnaire should be given 2 days
apart and 2 weeks apart and at similar times of the day, and
the ICC compared between the 1st and 2nd interviews and
the 1st and 3rd interviews.
It was shown that the MG-QOL15(T) also had a good
concurrent validity. In this study, the MG-QOL15(T) score
was found to be correlated with physical functioning,
general health, vitality, social functioning domains, and
the physical and the mental composite scores of the SF-36,
which concurs with the study examining the original MGQOL15 (4). This means that the higher the MG-QOL15(T)
score (for example, more symptoms and incapacity, which
causes worse QOL), the worse the perception of general
health status, vitality, and physical and social functioning
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by the patient. Furthermore, the higher the MGQOL15(T) score, the worse is the mental composite score
of SF-36. Other than the original study, the physical and
mental aspects of health-related QOL questionnaires were
also found to be affected in MG (2,3,12,13). On top of all
this, other than this negative correlation between the MGQOL15(T) score and the above-mentioned domains of the
SF-36, score 0 (not at all) was rarely chosen for items 1
and 7 in both evaluations, and 11 in the second evaluation
(i.e. those items reflecting the psychological, social, and
occupational domains (5), which were also in accordance
with the above-mentioned facts.
Apart from disease severity, other disease-related
factors, such as depression, anxiety, drug treatment, and
the number of myasthenic crises may influence QOL in
MG (3). However, this was outside the scope of this study.
The pros of this study were that the CA value was high in
the 11 patients and higher in the 23 patients. Furthermore,
ICC and r values were found to be very high for the selected
group of MG patients. The main limitation of our study was
the small sample size. The cultural adaptation studies of
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MG-QOL15 in different cultures were conducted with 10
(monocenter) to 327 patients (multicenter) (3,12). Because
this study was monocenter and conducted in a small
city university hospital, involving only clinically stable
voluntary patients, we could not enlarge our sample size.
However, small sample size generally causes statistically
insignificant results, which was not observed in this study.
In our study, CA values were found to be high not only
in 23 patients but also in 11 patients. From this point of
view, it could be assumed that statistically significant
results in 11 patients in test–retest reliability and validity
evaluations could indicate statistically significant results
with larger groups. Therefore, it is clearly warranted that
the MG-QOL15 (T) should be repeated and validated in
larger populations.
In conclusion, we created a Turkish version of the
MG-QOL15 and evaluated its validity and reliability. The
MG-QOL15(T) functions as a valid, reliable, valuable

tool for measuring disease-specific health related-QOL in
Turkish patients with MG. It can be considered a reliable
tool to evaluate the physical, psychological, and social
well-being of Turkish patients with MG. This instrument
could provide additional assistance in clinical evaluations
of Turkish patients with MG and could be used in research
studies of QOL in MG. We recommend that our findings
be repeated in a multicenter or any other large prospective
cohorts of clinically stable MG patients.
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Age

MG com

MG-QOL15(T)

PF

RP

BP

GH

VT

SF

RE

MH

PCS

SF-36

MG com

MGQOL15(T)

PF

RP

BP

GH

VT

SF

RE

MH

PCS

MCS

r

0.238

0.037

- 0.339

- 0.385

- 0.051

- 0.009

- 0.237

- 0.333

- 0.138

0.083

- 0.349

- 0.198

P

0.273

0.866

0.308

0.242

0.882

0.979

0.482

0.317

0.686

0.808

0.293

0.560

N

23

23

11

11

11

11

11

11

11

11

11

11

r

0.555

- 0.726

- 0.487

- 0.284

- 0.413

- 0.305

- 0.472

- 0.676

0.005

- 0.639

- 0.227

P

0.006

0.011

0.129

0.397

0.207

0.361

0.142

0.022

0.989

0.034

0.501

N

23

11

11

11

11

11

11

11

11

11

11

r

- 0.841

- 0.551

- 0.441

- 0.778

- 0.771

- 0.833

- 0.485

- 0.556

- 0.779

- 0.753

P

0.001

0.079

0.175

0.005

0.005

0.001

0.131

0.076

0.005

0.007

N

11

11

11

11

11

11

11

11

11

11

r

0.505

0.581

0.830

0.732

0.730

0.605

0.443

0.878

0.604

P

0.113

0.061

0.002

0.010

0.011

0.049

0.172

0.000

0.049

N

11

11

11

11

11

11

11

11

11

r

- 0.024

0.353

0.372

0.629

0.795

0.213

0.604

0.624

P

0.943

0.287

0.260

0.038

0.003

0.529

0.049

0.040

N

11

11

11

11

11

11

11

11

r

0.505

0.232

0.310

- 0.145

0.428

0.741

0.154

P

0.113

0.492

0.353

0.671

0.190

0.009

0.652

N

11

11

11

11

11

11

11

r

0.758

0.651

0.529

0.762

0.656

0.749

P

0.007

0.030

0.095

0.006

0.028

0.008

N

11

11

11

11

11

11

r

0.809

0.494

0.620

0.521

0.818

P

0.003

0.122

0.042

0.100

0.002

N

11

11

11

11

11

r

0.579

0.622

0.693

0.867

P

0.062

0.041

0.018

0.001

N

11

11

11

11

r

0.265

0.433

0.618

P

0.431

0.183

0.043

N

11

11

11

r

0.379

0.817

P

0.250

0.002

N

11

11

r

0.506

P

0.113

N

11

MG com: Myasthenia gravis composite, MG-QOL15(T): The Turkish version of myasthenia gravis quality of life 15-item scale, SF-36: The Turkish version of the Medical
Outcomes Study 36-item short-form health survey (SF-36), PF: Physical functioning, RP: Role functioning physical, BP: Bodily pain, GH: General health, VT: Vitality, SF:
Social functioning, RE: Role functioning emotional, MH: Mental health, PCS: Physical composite score, MCS: Mental composite score
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